Search

everythinglearnresearchcommunity

for

Search:↓

The user is considering using Minoxidil and Tretinoin to manage hair loss while waiting for Breezula/PP405, as they cannot tolerate dutasteride or finasteride. They hope these treatments will help retain hair despite ongoing loss.

A user is seeking hair loss treatments without using systemic DHT blockers like finasteride due to side effects. Suggestions include clascoterone (not FDA approved), pyrilutamide, RU58841, and low-dose topical finasteride, with a recommendation to consult a doctor.

Pyrilutamide is a selective AR antagonist with a high binding affinity, making it effective in competing with DHT for androgen receptors. The 1% concentration is more effective than the 0.5%, but the latter may suffice for mild hair loss; the drug is considered a good option for those avoiding 5AR blockers due to side effects.

Hair loss treatments Finasteride, Dutasteride, Pyrilutamide, and RU58841 have different mechanisms of action. They can be used individually or stacked for better protection against hair loss.

The user is considering starting Minoxidil and is looking for a topical solution to combine with it. They are confused about which product to prioritize among options like RU58841, Pyrilutamide, FinaTopic, and DutaTopic.

Sprocketshead asks if pyrilutamide can be applied with minoxidil, and inquires about its consistency and odor. They want to know if it's more high maintenance than topical minoxidil.

The conversation discusses a last-resort hair loss treatment combining topical finasteride, minoxidil, melatonin, and progesterone, with claims that topical finasteride can inhibit up to 52% of scalp DHT. One reply clarifies that progesterone is not an anti-androgen but has anti-androgenic properties because it competes with androgens for receptors.

Clascoterone is considered overhyped and not as effective as finasteride or dutasteride, but it may be useful as a supportive treatment in combination with other therapies. Users express skepticism about its effectiveness compared to clinical trials, with some suggesting it could be beneficial for those who cannot tolerate other treatments.

User is on vacation in Greece and wants to buy tretinoin or isotretinoin to improve Minoxidil absorption. They are considering isotretinoin since it is available over-the-counter in Greece but requires a prescription back home.

A user is considering using topical finasteride, topical minoxidil, RU58841, and dermarolling twice a week to address hair loss after experiencing side effects with oral finasteride. They previously saw positive results with a topical spray containing finasteride, minoxidil, and tretinoin but discontinued use due to laziness.

Breezula's phase 2 showed reduced efficacy after 6 months, but phase 3 had positive results, causing confusion about any changes made to the drug. There is frustration over the long timeline for hair loss treatments, with some users expressing more interest in other potential treatments like GT-20029.

The conversation discusses hair loss treatments, mentioning minoxidil, finasteride, RU58841, VDPHL, GT20029, and follicle cloning as potential solutions. It also reveals that the discussion about PP405 was an April Fool's joke.

Discussing and researching different treatments for hair loss, including RU58841, Dutasteride, Spironolactone, Retin-A, Stemoxydine (Neogenic), Copper peptides, Superoxide Dismutase, NANO, and Eucapil.

The user switched from finasteride to 2.5 mg dutasteride daily and added 1% pyrilutamide to address persistent scalp itch, but the itch remains. They also use 2% ketoconazole and 2.5% selenium sulfide shampoo for temporary relief.

The user experienced a slight decrease in hair shedding and scalp itch, and reduced sebum production using Pyrilutamide, but stopped due to chest pain, breathing difficulties, and heart issues. They felt normal a week after discontinuing and doubted FDA approval for the drug.

The conversation discusses using liquid cetirizine as a topical treatment for hair loss. It mentions Minoxidil, finasteride, and RU58841 as other treatments.

The conversation discusses using topical Calcipotriol and Valproic Acid for hair loss, focusing on their mechanisms involving the VDR receptor and Wnt/beta-catenin pathway. Specific treatments mentioned are Minoxidil, Finasteride, and RU58841.

Hair loss itch stopped by adding RU58841 to treatment. Topical Finasteride and Pyrilutamide also mentioned as potential itch solutions.

A user was prescribed Alpicort E, which contains Estradiol Benzoate, Prednisone, and Salicylic Acid, for hair loss and is seeking others' experiences due to concerns about potential side effects.

The conversation discusses the effectiveness and safety of hair loss treatments, specifically RU58841 and Pyrilutimide (Pyril), with users sharing that Pyril was no more effective than a placebo and expressing concerns about the safety of RU58841 based on personal experiences and the lack of pharmaceutical interest.

The conversation is about the difficulty of applying both pyril and min/fin to treat hair loss twice daily and whether combining them yields positive results.

RU58841 had mixed results for hair regrowth, with some users experiencing no change and others noting regrowth but also side effects like libido issues and chest pain. Some users combined it with other treatments like finasteride and dutasteride, with varying effectiveness.

The conversation discusses using RU58841 with octopirox or essential oils for hair loss treatment. The user is seeking advice on which variation to try.

P5P supplementation helped reverse finasteride side effects, particularly by lowering prolactin levels and restoring sensitivity. The user experienced significant improvement within a day and full recovery in a few days.

The conversation is about when GT20029, a hair loss treatment, might be available on the grey market, with users discussing the challenges of compounding it and speculating it might be available after phase 2 results, similar to pyri. Specific treatments mentioned are pyri, RU58841, and GT20029.

The user is hesitant to use finasteride due to potential hormonal side effects and is waiting for the release of pyrilutamide, a new hair loss treatment. Other users suggest trying finasteride, warning about potential regret if hair loss progresses in the meantime.

GT20029 and pyrilutamide are both androgen antagonists but work differently; GT20029 degrades the androgen receptor, while pyrilutamide blocks DHT from binding. GT20029 is expected to have similar efficacy to CosmeRNA.

Considering treatments for hair loss, including Minoxidil, Finasteride, RU58841, Fluridil and Pyrilutamide. The user is weighing the risks of taking unapproved medication before it has been mass produced.

Clascoterone's full trial results are expected by mid-July 2026, but skepticism exists about timely release. Clascoterone is available at 5% from some telehealth companies.

The user has been using RU58841 for 6 months without noticeable results and is considering dropping it while continuing oral minoxidil, daily dutasteride, and topical minoxidil. Another user suggests visiting a dermatologist to check for other conditions.